Heptor-Pharmex granules 3 g package 5 g No. 30

Heptor-Pharmex granules are used to treat concomitant diseases and complications caused by impaired liver detoxification function (for example, in cirrhosis of the liver) with symptoms of latent or pronounced hepatic encephalopathy.

Composition

The active ingredient is L-ornithine-L-aspartate (1 packet contains 3 g of L-ornithine-L-aspartate).

Excipients: fructose, anhydrous citric acid, povidone K25, sodium saccharin (E 954), sodium cyclamate (E 952), "Orange" flavoring, "Lemon" flavoring, "Sunset" dye (E 110).

Contraindication

Hypersensitivity to L-ornithine-L-aspartate, Sunset dye (E 110) or to any of the excipients of the drug.

Severe renal dysfunction (chronic or acute renal failure). Do not use Heptor-Pharmex (granules) if creatinine level is above 3 mg/100 ml.

Method of application

Dissolve the contents of 1-2 packets of Heptor-Pharmex in a large amount of liquid (e.g. a glass of water or juice) and take during or after meals. Take up to 3 times a day.

The duration of treatment is determined by the doctor depending on the patient's clinical condition.

Application features

Pregnant women

The use of Heptor-Pharmex granules during pregnancy should be avoided. However, if treatment with the drug during pregnancy is considered necessary for vital indications, the doctor should carefully weigh the ratio of the possible risk to the fetus (child) / the expected benefit to the mother.

It is not known whether L-ornithine-L-aspartate passes into breast milk. Therefore, the use of Heptor-Pharmex should be avoided during breastfeeding.

Children

Experience with the drug in children is limited, so it should not be used in pediatric practice.

Drivers

Due to the disease, the ability to drive or operate other machinery may be impaired during treatment with L-ornithine-L-aspartate, so such activities should be avoided during the treatment period.

Overdose

In case of overdose, an increase in urea levels in the blood and urine may occur.

So far, no signs of intoxication caused by an overdose of L-ornithine-L-aspartate have been observed. Side effects may be exacerbated. In case of overdose, symptomatic treatment is recommended.

Side effects

Gastrointestinal: infrequently (≥ 1/1000, <1/100) - nausea, vomiting, stomach pain, flatulence, diarrhea, constipation.

Musculoskeletal system: very rarely (<1/10,000) - pain in the joints and muscles.

Skin and subcutaneous tissue disorders: skin rash, redness of the skin, itching, urticaria.

Neurological disorders: dizziness.

Immune system disorders: hypersensitivity reactions, including angioedema, anaphylactic shock, sneezing, lacrimation.

Metabolic disorders: when used in large doses, an increase in uric acid levels in blood plasma is possible.

These adverse reactions are usually short-lived and do not require discontinuation of the drug.

The dye "Sunset" (E 110) may cause allergic reactions.

Storage conditions

Store in the original packaging at a temperature not exceeding 25 °C, out of the reach of children.

Shelf life - 2 years.